CHICAGO, September 15 (Hfrance.fr) - New data from (MRNA.O) big essay vaccine release shows the protection it offers wanes over time, supporting the case for booster doses, the company said in a press release Wednesday.
Several recent studies have suggested that his vaccine might have an advantage over a similar shot from Pfizer Inc (PFE.N) and German partner BioNTech SE in terms of maintaining efficiency over time.
Experts said the difference is likely due to Moderna's higher dose of messenger RNA (mRNA) and the slightly longer interval between first and second shot.
Both vaccines have been shown to be extremely effective in preventing diseasein their r large phase III studies.
The analysis released Wednesday, however, showed a flaw in the armor of the Moderna shot over time, with higher rates of in people vaccinated about 13 months ago compared to those vaccinated about eight months ago. The study has not yet been peer reviewed.
Moderna submitted its application on September 1 to the United States Food and Drug Administration for authorization of a recall. learn more
The information documents of the analysis by The FDA's Pfizer recall request, released earlier Wednesday, suggests that a key issue the agency will look into is whether vaccine protection wanes . Previous data on Moderna avaien shootingt showed lasting protection n, which makes the case of boosters more difficult.
In the new analysis, Moderna compared the performance of the vaccine in more than 14,000 volunteers vaccinated between July and October 2020 to some 11,000 volunteers from the placebo group who were offered the vaccine between December 2020 and March 2022 following its authorization for emergency use in United States.
They identified 88 cases of COVID-19 among those who received both vaccines more recently, compared to 162 cases among those vaccinated l 'last year. Overall, however, only 19 cases were considered serious, a key benchmark in the assessment of diminished protection.
Moderna said there was a downward trend in the rate of severe cases. among the most recently vaccinated, although the result is not statistically significant.
The company said the decrease in immunity seen in the new analysis adds to the evidence that a booster is needed.
The company also highlighted two studies showing lasting protection against serious illnesses.
In a study conducted with Kaiser Permanente Southern California while the highly transmissible Delta variant was circulating, researchers found that the Moderna vaccine was 87% effective in preventing a diagnosis of COVID-19 and 96% effective in preventing hospitalization.
They had analyzed data on more than 352,000 people who had received two doses of Moderna co vaccine compared to the same number of unvaccinated individuals of different ages. and similar risk factors.
Moderna also pointed out a study released last week by the Centers forUnited States Disease Control and Prevention. looking at data from more than 32,000 visits to emergency care facilities, emergency rooms and hospitals in nine states or major cities.
He found the Moderna e vaccine to be 95% effective in preventing hospitalization in people of all ages, compared to 80% for the Pfizer / BioNTech vaccine and 60% for the Johnson & Johnson vaccine (JNJ.N) . Report by Julie Steenhuysen Edited by Bill Berkrot
Our standards: The Thomson Hfrance.fr Trust Principles.